ArticleCell reports2018
DNA-PK Is Targeted by Multiple Vaccinia Virus Proteins to Inhibit DNA Sensing.
Article in Cell reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- A viral ORFeome library for systems-level genetic dissection of host-pathogen interactions.Cell · 2026Article
- DNA-PK interacts with cyclic dinucleotides and inhibits type I interferon responses.The Journal of experimental medicine · 2026Article
- Vaccinia Virus-A Swiss Army Knife Against Cancer.Cancers · 2025Review
- Review
- The unique immune evasion mechanisms of the mpox virus and their implication for developing new vaccines and immunotherapies.Virologica Sinica · 2024Review
- The monkeypox virus-host interplays.Cell insight · 2024Review
- Birth of protein folds and functions in the virome.Nature · 2024Article
- Filamin B restricts vaccinia virus spread and is targeted by vaccinia virus protein C4.Journal of virology · 2024Article
- Article
- Monkeypox Virus (MPXV) Infection: A Review.Infectious disorders drug targets · 2024Review
- CBASS to cGAS-STING: The Origins and Mechanisms of Nucleotide Second Messenger Immune Signaling.Annual review of virology · 2023Review
- Improving poxvirus-mediated antitumor immune responses by deleting viral cGAMP-specific nuclease.Cancer gene therapy · 2023Article
- Vaccinia E5 is a major inhibitor of the DNA sensor cGAS.Nature communications · 2023Article
- Diabetes mellitus: Lessons from COVID-19 for monkeypox infection.Primary care diabetes · 2023Review
- Targeting DNA-PK.Cancer treatment and research · 2023Article
- Poxviruses and the immune system: Implications for monkeypox virus.International immunopharmacology · 2022Review
- Structural basis for the inactivation of cytosolic DNA sensing by the vaccinia virus.Nature communications · 2022Article
- African Swine Fever Virus EP364R and C129R Target Cyclic GMP-AMP To Inhibit the cGAS-STING Signaling Pathway.Journal of virology · 2022Article
- Poxvirus Recombination.Pathogens (Basel, Switzerland) · 2022Review
- Dysregulation of Cellular VRK1, BAF, and Innate Immune Signaling by the Vaccinia Virus B12 Pseudokinase.Journal of virology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Virus infection is sensed by pattern recognition receptors (PRRs) detecting virus nucleic acids and initiating an innate immune response. DNA-dependent protein kinase (DNA-PK) is a PRR that binds cytosolic DNA and is antagonized by vaccinia virus (VACV) protein C16. Here, VACV protein C4 is also shown to antagonize DNA-PK by binding to Ku and blocking Ku binding to DNA, leading to a reduced production of cytokines and chemokines in vivo and a diminished recruitment of inflammatory cells. C4 and C16 share redundancy in that a double deletion virus has reduced virulence not seen with single deletion viruses following intradermal infection. However, non-redundant functions exist because both single deletion viruses display attenuated virulence compared to wild-type VACV after intranasal infection. It is notable that VACV expresses two proteins to antagonize DNA-PK, but it is not known to target other DNA sensors, emphasizing the importance of this PRR in the response to infection in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.